Medtronic stock (IE00BTN1Y115): focus on latest earnings and pipeline updates

Medtronic recently reported quarterly results and highlighted its medical device pipeline, offering investors fresh insight into growth drivers and profitability trends.

Medtronic reported results for its fiscal third quarter 2025 on February 18, 2025, with management emphasizing stable revenue growth and ongoing portfolio optimization, according to a company release published that day on its investor relations site and covered by Reuters on February 18, 2025.Medtronic IR as of 02/18/2025 The company also continued to highlight progress in key product categories such as cardiac devices and diabetes technologies, underlining its strategy to balance innovation with cost discipline.Reuters as of 02/18/2025

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Medtronic plc
• Sector/industry: Medical technology / medical devices
• Headquarters/country: Dublin, Ireland
• Core markets: Global, with significant exposure to the US healthcare market
• Key revenue drivers: Cardiac and vascular devices, surgical products, neuroscience and diabetes technologies
• Home exchange/listing venue: New York Stock Exchange (ticker: MDT)
• Trading currency: USD

Medtronic: core business model

Medtronic is a large global medical technology company focused on devices and therapies used primarily in hospital and clinical settings. The group designs and manufactures products that support the diagnosis and treatment of chronic diseases, including cardiovascular conditions, neurological disorders and diabetes. Its business model combines hardware-based implants and instruments with software and monitoring solutions that can generate recurring revenue streams.

The company historically organized operations into major segments such as Cardiovascular, Medical Surgical, Neuroscience and Diabetes, serving physicians, hospitals and health systems. Revenue is driven by procedure volumes, demographics such as aging populations, and the adoption of advanced minimally invasive techniques. Contracts with hospital systems and group purchasing organizations are important channels, and pricing is influenced by reimbursement dynamics in the United States and other key markets.

Medtronic’s strategy has emphasized steady investment in research and development to support incremental innovation in existing franchises and selective entry into new high-growth adjacencies. At the same time, management has pursued portfolio actions including divestitures and spin-offs to sharpen focus on core categories. The company also leverages its global footprint to launch products internationally and manage supply chains at scale.

Main revenue and product drivers for Medtronic

In its fiscal 2025 third quarter, Medtronic reported revenue of approximately $8.1 billion, reflecting low- to mid-single-digit growth compared with the prior-year period, according to the company’s February 18, 2025, earnings release.Medtronic IR as of 02/18/2025 Cardiovascular therapies, including cardiac rhythm management, structural heart and coronary products, represented a major share of sales and benefited from procedural volume trends. Surgical and patient monitoring solutions also contributed as hospitals continued to invest in minimally invasive and robotics-assisted procedures.

The Neuroscience segment, which encompasses spine, neuromodulation and other related products, remained another important revenue contributor. Demand in these categories is influenced by access to care, the adoption of new technologies and competition from other device companies. Medtronic’s Diabetes segment, while smaller than its cardiovascular businesses, is strategically important as it develops insulin pumps and continuous glucose monitoring systems that aim to improve glycemic control for people with diabetes.

Profitability in the quarter was supported by cost measures and product mix, with management noting adjusted earnings per share performance that aligned with its full-year objectives, according to the same February 18, 2025, statement.Medtronic IR as of 02/18/2025 Currency movements, supply chain expenses and pricing dynamics remained factors to watch, particularly for US investors focused on margins and the ability to fund ongoing research and shareholder returns.

Conclusion

Medtronic remains a large diversified player in medical technology, with fiscal 2025 third-quarter results illustrating the importance of cardiovascular and surgical products alongside growing diabetes and neuroscience franchises. For US investors, the New York–listed stock offers exposure to hospital procedure trends, innovation in devices and evolving reimbursement environments. Future performance will depend on the company’s ability to advance its pipeline, manage competition and execute portfolio strategies while navigating regulatory and pricing pressures in key markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.